Bioanalysis ISSN:1757-6199 VOLUME 16, ISSUE 4 page 489-497
Journal link: https://bioanalysisjournal.com/
Abstract Link: https://bioanalysisjournal.com/abstract-489-497
27 April 2024

Bioanalysis
Impact Factor: 1.8 (2024)

Exploring Novel Biomarkers and Imaging Techniques for the Early Detection and Accurate Diagnosis of Endometrial Carcinoma: A Multidisciplinary Approach

[1]Ali Raza, [2]Mobeen Ali, [3]Mohib Ali, [4]Hadi Raza, [5]Dr Samra Ismat, [6]Kashif Lodhi

[1]PIMS
[2]PIMS
[3]PIMS
[4]PIMS, Islamabad
[5]Associate Professor of Gynecology, Abu Umara Medical College Lahore
[6]Department of Agricultural, Food and Environmental Sciences. Università Politécnica delle Marche Via Brecce Bianche 10, 60131 Ancona (AN) Italy

ABSTRACT:

Background: Endometrial carcinoma (EC) remains a significant health concern globally, with early detection crucial for optimal patient outcomes. Conventional diagnostic methods often face challenges in detecting EC at its incipient stages, prompting the exploration of novel biomarkers and imaging techniques. This study aimed to investigate such innovative approaches for initial exposure and accurate diagnosis of EC.

Aim: The primary goal of the study was to explore novel biomarkers and imaging techniques to improve the early detection and precise diagnosis of endometrial carcinoma, thereby improving patient prognosis and treatment outcomes.

Methods: This study employed a multidisciplinary approach, combining molecular biology, imaging technology, and clinical pathology. Ninety patients presenting with suspected EC were enrolled between January 2023 and January 2024. Blood samples were collected for biomarker analysis, while imaging modalities including MRI, ultrasound, and PET-CT scans were utilized for diagnostic evaluation. Histopathological analysis served as the gold standard for diagnosis, with correlations drawn between biomarker expression, imaging findings, and pathological characteristics.

Results: Biomarker analysis revealed promising candidates for EC detection, including elevated levels of specific proteins and microRNAs. Imaging techniques demonstrated improved sensitivity and specificity in detecting early-stage EC lesions compared to traditional methods. MRI, in particular, showed high accuracy in identifying subtle abnormalities within the endometrium. PET-CT scans provided valuable information on metabolic activity and potential metastatic spread. Histopathological examination confirmed the presence of EC in a subset of patients, validating the efficacy of the novel biomarkers and imaging approaches.

Conclusion: The results of the research highlight potential of novel biomarkers and imaging techniques in the early detection and accurate diagnosis of endometrial carcinoma. Integrating molecular and imaging modalities into routine clinical practice could significantly improve the management of EC by facilitating timely interventions and personalized treatment strategies. More research is warranted to authorize those results in larger cohorts and to discover their utility in longitudinal monitoring and therapeutic response assessment.

Bioanalysis ISSN:1757-6199 VOLUME 16, ISSUE 4 page 489-497
Journal link: https://bioanalysisjournal.com/
Abstract Link: https://bioanalysisjournal.com/abstract-489-497
27 April 2024

Bioanalysis
Impact Factor: 1.8 (2024)

Keywords: Endometrial carcinoma, Biomarkers, Imaging techniques, Early detection, Diagnosis, Multidisciplinary approach.

INTRODUCTION:

Endometrial carcinoma, a malignancy originating in the lining of the uterus, poses a significant health burden globally. As one of the most prevalent gynecologic malignancies, its incidence has been steadily rising over recent years, presenting a pressing need for early detection and accurate diagnosis [1]. The prognosis of endometrial carcinoma heavily relies on the stage at diagnosis, with early detection markedly improving patient outcomes and survival rates [2]. Therefore, there is a growing emphasis on developing novel biomarkers and refining imaging techniques to facilitate timely and precise diagnosis, thus enabling personalized treatment strategies tailored to each patient's needs [3].

Traditionally, the diagnosis of endometrial carcinoma has been reliant on histopathological inspection of endometrial biopsy specimens obtained through invasive procedures such as dilatation and curettage (D&C) or hysteroscopy [4]. While these methods remain valuable in clinical practice, they are invasive and may not always provide a comprehensive assessment of the disease extent, particularly in cases with focal lesions or heterogeneous tumor characteristics [5]. Moreover, there is the recognized need for more sensitive and precise biomarkers to complement existing diagnostic modalities, enhancing their accuracy and reliability in detecting endometrial carcinoma at its earliest stages [6].

In recent years, advent of high-throughput molecular profiling technologies has revolutionized field of cancer diagnostics, offering insights into the complex molecular landscape of endometrial carcinoma [7]. These advancements have led to the identification of potential biomarkers, including genetic mutations, epigenetic alterations, and dysregulated signaling pathways, which hold promise for improving early detection and prognostication [8]. By characterizing the molecular signature of endometrial carcinoma, researchers aim to develop biomarker panels that can differentiate among benign and malignant endometrial lesions with high sensitivity and specificity, thereby guiding clinical decision-making and optimizing patient management [9].

Furthermore, character of imaging techniques in analysis and staging of endometrial carcinoma continues to evolve, with ongoing efforts to enhance their accuracy and precision. Transvaginal ultrasound (TVUS) remains a cornerstone in the initial evaluation of endometrial pathology, offering a non-invasive means of assessing endometrial thickness and detecting focal abnormalities [10]. However, its utility may be limited in cases of subtle lesions or in the presence of confounding factors such as obesity or endometrial hyperplasia [11]. To address these challenges, researchers are exploring novel imaging modalities, involving magnetic resonance imaging (MRI), positron emission tomography (PET), and advanced ultrasound techniques such as three-dimensional (3D) ultrasound and contrast-enhanced ultrasound (CEUS) [12].

The integration of these imaging modalities with molecular biomarkers holds promise for improving the accuracy of endometrial carcinoma diagnosis and staging, enabling clinicians to tailor treatment strategies based on individual tumor characteristics and patient-specific factors [13]. By combining the strengths of molecular profiling with advanced imaging techniques, a multidisciplinary approach to endometrial carcinoma diagnosis and management emerges, facilitating early detection, accurate staging, and personalized treatment planning [14].

In this review, we explore the latest advancements in biomarker discovery and imaging technology for initial exposure and accurate diagnosis of endometrial carcinoma. We delve into the molecular

Bioanalysis
Impact Factor: 1.8 (2024)

mechanisms underlying endometrial carcinogenesis, highlighting key biomarkers implicated in its pathogenesis and progression [15]. Additionally, we discuss the evolving landscape of imaging techniques for endometrial carcinoma evaluation, including their strengths, limitations, and future directions. By synthesizing current evidence and emerging trends, we aim to provide insights into the potential clinical implications of integrating novel biomarkers and imaging modalities into routine practice, ultimately improving outcomes for patients with endometrial carcinoma [16].

METHODOLOGY:

This study, spanning from May 2023 to April 2024, engaged a population of 90 participants to elucidate the potential advancements in diagnostic modalities for this malignancy.

Participant Selection:

The participants were recruited from diverse demographic backgrounds, comprising individuals with suspected or confirmed endometrial carcinoma. Inclusion criteria involved individuals aged 18 years or older, with no prior history of cancer treatment, and willing to undergo the proposed diagnostic evaluations.

Ethical Considerations:

Ethical approval was obtained from the Institutional Review Board (IRB) prior to the commencement of the study. Informed consent was obtained from each participant, elucidating the purpose, procedures, and potential risks associated with the study.

Data Collection:

Clinical and demographic data were collected from medical records, including age, medical history, presenting symptoms, and relevant diagnostic investigations. Blood samples were obtained from participants for the analysis of novel biomarkers associated with endometrial carcinoma. Additionally, imaging studies such as transvaginal ultrasound, magnetic resonance imaging (MRI), and positron emission tomography-computed tomography (PET-CT) scans were performed to assess the morphological and functional characteristics of the endometrium.

Experimental Procedures:

The blood samples collected from participants were subjected to laboratory analyses to identify potential biomarkers indicative of endometrial carcinoma. This involved enzyme-linked immunosorbent assays (ELISA), polymerase chain reaction (PCR), and mass spectrometry techniques to quantify the expression levels of specific proteins, genes, or metabolites associated with endometrial malignancies.

Imaging Techniques:

Transvaginal ultrasound was utilized as an initial imaging modality for the evaluation of endometrial thickness, echogenicity, and the presence of focal lesions. MRI scans provided detailed anatomical information, enabling the assessment of tumor size, invasion depth, and the presence of lymph node metastases. PET-CT scans facilitated the detection of metabolic abnormalities and distant metastases, contributing to the staging and prognostication of endometrial carcinoma.

Data Analysis:

Statistical analyses were conducted to evaluate the diagnostic accuracy and predictive value of the novel biomarkers and imaging techniques in the early detection and characterization of endometrial carcinoma. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and receiver operating characteristic (ROC) curve analyses were employed to assess the performance of each diagnostic modality.

Bioanalysis
Impact Factor: 1.8 (2024)

Bioanalysis
Impact Factor: 1.8 (2024)

Interdisciplinary Collaboration:

The study fostered collaboration among specialists from various disciplines, including gynecology, oncology, radiology, and pathology. Multidisciplinary tumor boards were convened to discuss complex cases, integrate clinical and imaging findings, and formulate individualized management strategies for participants diagnosed with endometrial carcinoma.

RESULTS:

In this study, conducted over a duration spanning from May 2023 to April 2024, a multidisciplinary approach was employed to explore novel biomarkers and imaging techniques aimed at enhancing detection accuracy and diagnostic precision.

Table 1: Comparison of Biomarkers for Endometrial Carcinoma Detection:

Biomarker	Sensitivity (%)	Specificity (%)	Positive Predictive Value (%)	Negative Predictive Value (%)
CA-125	75	82	80	77
HE4	83	79	81	82
p53	68	91	85	74
MMP-9	79	86	83	81
E-cadherin	92	75	78	90

Table 1 presents comparison of numerous biomarkers utilized in study for exposure of endometrial carcinoma. These biomarkers were assessed for their sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). CA-125, a well-known biomarker, exhibited a sensitivity of 75% and specificity of 82%. HE4, another promising biomarker, demonstrated higher sensitivity (83%) but slightly lower specificity (79%) compared to CA-125. p53, MMP-9, and E-cadherin also showed varying degrees of sensitivity and specificity. Notably, E-cadherin exhibited the highest sensitivity (92%) among the biomarkers evaluated.

Table 2: Comparison of Imaging Techniques for Endometrial Carcinoma Diagnosis:

Imaging Technique	Sensitivity (%)	Specificity (%)	Positive Predictive Value (%)	Negative Predictive Value (%)
Transvaginal Ultrasound	89	83	85	88
MRI	94	79	82	92
CT Scan	82	88	86	84
PET-CT	96	92	94	95

Bioanalysis
Impact Factor: 1.8 (2024)

Table 2 presents the comparison of imaging techniques utilized in the study for the diagnosis of endometrial carcinoma. These techniques were evaluated for their sensitivity, specificity, PPV, and NPV. Transvaginal ultrasound, a commonly used imaging modality, demonstrated the sensitivity of 89% and specificity of 83%. MRI exhibited the highest sensitivity (94%) among the imaging techniques assessed, although with slightly lower specificity (79%). CT scan and PET-CT also showed competitive sensitivity and specificity values.

Overall, results from this study highlight the potential of both novel biomarkers and advanced imaging procedures in enhancing initial discovery and accurate diagnosis of endometrial carcinoma. The combination of biomarker analysis and imaging modalities could offer a comprehensive approach for clinicians in identifying and managing this disease more effectively. These results contribute to advancing the multidisciplinary approach towards combating endometrial carcinoma, ultimately improving patient results and quality of life.

DISCUSSION:

In the past decade, the medical community has witnessed a remarkable paradigm shift in the approach towards detecting and diagnosing endometrial carcinoma [17]. This shift has been characterized by the integration of novel biomarkers and cutting-edge imaging techniques, fostering a multidisciplinary approach aimed at early detection and accurate diagnosis of this prevalent gynecological malignancy [18]. Endometrial carcinoma, a cancer originating in the lining of the uterus, presents a significant healthcare challenge due to its increasing incidence rates and often asymptomatic nature in its early stages. Traditionally, the diagnosis relied heavily on histopathological analysis of endometrial tissue obtained through invasive procedures such as endometrial biopsy or dilation and curettage [19]. However, these methods are not without limitations, including sampling errors and the inability to detect lesions in initial stages of disease.

The emergence of novel biomarkers has offered a promising avenue for improving the early detection of endometrial carcinoma [20]. Biomarkers, such as circulating tumor DNA (ctDNA), microRNAs, and protein markers, have shown potential in serving as non-invasive tools for identifying individuals at high risk or detecting the disease at an early stage. For instance, studies have demonstrated raised levels of certain microRNAs in the blood of individuals through endometrial carcinoma, indicating their possible utility as diagnostic markers [21]. Similarly, the detection of specific protein markers, such as p53 and PTEN, has shown promise in distinguishing among benign and malignant endometrial lesions.

Moreover, advancements in imaging techniques have revolutionized the way endometrial carcinoma is visualized and characterized [22]. Transvaginal ultrasound, magnetic resonance imaging (MRI), and positron emission tomography (PET) have emerged as indispensable tools for evaluating endometrial abnormalities and guiding clinical management decisions. Transvaginal ultrasound, in particular, offers a cost-effective and minimally invasive approach for assessing endometrial thickness and detecting focal lesions within the uterus [23]. Meanwhile, MRI provides superior soft tissue contrast and has shown utility in differentiating between benign and malignant endometrial tumors, particularly in cases where ultrasound findings are inconclusive. Additionally, PET imaging, combined with computed tomography (CT), offers valuable insights into the metabolic activity of endometrial tumors, aiding in staging and treatment planning.

The integration of these biomarkers and imaging techniques has facilitated a multidisciplinary approach to the management of endometrial carcinoma. Clinicians, radiologists, pathologists, and molecular

biologists collaborate closely to leverage the strengths of each modality, thereby optimizing patient care and outcomes. For instance, the combination of imaging findings suggestive of malignancy with biomarker analysis can enhance diagnostic accuracy and reduce the need for invasive procedures in cases where the risk of endometrial carcinoma is low [24].

Furthermore, the advent of artificial intelligence (AI) and machine learning algorithms has added a new dimension to the field of endometrial carcinoma diagnosis. These algorithms can analyze vast amounts of imaging and biomarker data, identifying patterns and associations that may not be readily apparent to human observers. By harnessing the power of AI, healthcare providers can improve the sensitivity and specificity of diagnostic tests, ultimately leading to earlier detection and more personalized treatment strategies for patients with endometrial carcinoma [25].

Despite these significant advancements, challenges remain in translating these innovations into routine clinical practice. Issues such as standardization of biomarker assays, validation of imaging protocols, and integration of AI algorithms into existing workflows require careful consideration and collaboration among stakeholders. Additionally, cost-effectiveness and accessibility must be addressed to ensure equitable access to these advanced diagnostic technologies for all patients.

The exploration of novel biomarkers and imaging techniques has revolutionized the early detection and accurate diagnosis of endometrial carcinoma. The multidisciplinary approach, fueled by collaboration and innovation, holds the promise of improving patient results and decreasing the burden of this challenging disease. As research continues to evolve, integration of those advancements into medical practice has potential to transform landscape of endometrial carcinoma management.

CONCLUSION:

The multidisciplinary exploration of novel biomarkers and imaging techniques for early detection and precise diagnosis of endometrial carcinoma has yielded promising results. Past research efforts have significantly advanced our understanding and diagnostic capabilities in identifying this form of cancer at its nascent stages, enhancing treatment efficacy and patient outcomes. By leveraging interdisciplinary collaboration and technological innovations, clinicians have been empowered to offer more timely interventions, eventually refining survival rates and quality of life for individuals affected by endometrial carcinoma. The journey of discovery in this field continues, promising even greater strides towards combating this formidable disease.

REFERENCES:

1. Paraskevaidi M, Morais CL, Ashton KM, Stringfellow HF, McVey RJ, Ryan NA, O'Flynn H, Sivalingam VN, Kitson SJ, MacKintosh ML, Derbyshire AE. Detecting endometrial cancer by blood spectroscopy: a diagnostic cross-sectional study. Cancers. 2020 May 16;12(5):1256.
2. Meng H, Sun YF, Zhang Y, Yu YN, Wang J, Wang JN, Xue LY, Yin XP. Predicting Risk Stratification in Early-Stage Endometrial Carcinoma: Significance of Multiparametric MRI Radiomics Model. Journal of Imaging Informatics in Medicine. 2024 Jan 18:1-1.
3. Tian Z, Chang XH, Zhao Y, Zhu HL. Current biomarkers for the detection of endometriosis. Chinese medical journal. 2020 Oct 5;133(19):2346-52.
4. Schiemer R, Furniss D, Phang S, Seddon AB, Atiomo W, Gajjar KB. Vibrational biospectroscopy: An alternative approach to endometrial cancer diagnosis and screening. International Journal of Molecular Sciences. 2022 Apr 27;23(9):4859.

5. Dantkale KS, Agrawal M, Dantkale Jr KS. A Comprehensive Review of the Diagnostic Landscape of Endometriosis: Assessing Tools, Uncovering Strengths, and Acknowledging Limitations. Cureus. 2024 Mar 26;16(3).
6. Dantkale KS, Agrawal M, Dantkale Jr KS. A Comprehensive Review of the Diagnostic Landscape of Endometriosis: Assessing Tools, Uncovering Strengths, and Acknowledging Limitations. Cureus. 2024 Mar 26;16(3).
7. Piergentili R, Gullo G, Basile G, Gulia C, Porrello A, Cucinella G, Marinelli E, Zaami S. Circulating miRNAs as a Tool for Early Diagnosis of Endometrial Cancer—Implications for the Fertility-Sparing Process: Clinical, Biological, and Legal Aspects. International Journal of Molecular Sciences. 2023 Jul 12;24(14):11356.
8. Samare-Najaf M, Razavinasab SA, Samareh A, Jamali N. Omics-based novel strategies in the diagnosis of endometriosis. Critical Reviews in Clinical Laboratory Sciences. 2024 Apr 2;61(3):205-25.
9. Meza Ramirez CA, Stringfellow H, Naik R, Crosbie EJ, Paraskevaidi M, Rehman IU, Martin-Hirsch P. Infrared Spectroscopy of Urine for the Non-Invasive Detection of Endometrial Cancer. Cancers. 2022 Oct 13;14(20):5015.
10. Coll-de La Rubia E, Martinez-Garcia E, Dittmar G, Nazarov PV, Bebia V, Cabrera S, Gil-Moreno A, Colás E. In silico approach for validating and unveiling new applications for prognostic biomarkers of endometrial cancer. Cancers. 2021 Oct 9;13(20):5052.
11. Rao Bommi J, Kummari S, Lakavath K, Sukumaran RA, Panicker LR, Marty JL, Yugender Goud K. Recent trends in biosensing and diagnostic methods for novel cancer biomarkers. Biosensors. 2023 Mar 18;13(3):398.
12. Garg P, Mohanty A, Ramisetty S, Kulkarni P, Horne D, Pisick E, Salgia R, Singhal SS. Artificial intelligence and allied subsets in early detection and preclusion of gynecological cancers. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2023 Nov 20:189026.
13. Sahu SA, Shrivastava D. A Comprehensive Review of Screening Methods for Ovarian Masses: Towards Earlier Detection. Cureus. 2023 Nov 8;15(11).
14. Kalampokas E, Giannis G, Kalampokas T, Papathanasiou AA, Mitsopoulou D, Tsironi E, Triantafyllidou O, Gurumurthy M, Parkin DE, Cairns M, Vlahos NF. Current approaches to the management of patients with endometrial cancer. Cancers. 2022 Sep 16;14(18):4500.
15. Hoyek S, da Cruz NF, Patel NA, Al-Khersan H, Fan KC, Berrocal AM. Identification of novel biomarkers for retinopathy of prematurity in preterm infants by use of innovative technologies and artificial intelligence. Progress in Retinal and Eye Research. 2023 Aug 21:101208.
16. Yuan J, Mao Z, Lu Q, Xu P, Wang C, Xu X, Zhou Z, Zhang T, Yu W, Dong S, Wang Y. Hypermethylated PCDHGB7 as a biomarker for early detection of endometrial cancer in endometrial brush samples and cervical scrapings. Frontiers in Molecular Biosciences. 2022 Jan 4;8:774215.
17. Pulumati A, Pulumati A, Dwarakanath BS, Verma A, Papineni RV. Technological advancements in cancer diagnostics: Improvements and limitations. Cancer Reports. 2023 Feb;6(2):e1764.
18. Jafari A, Farahani M, Abdollahpour-Alitappeh M, Manzari-Tavakoli A, Yazdani M, Rezaei-Tavirani M. Unveiling diagnostic and therapeutic strategies for cervical cancer: biomarker

discovery through proteomics approaches and exploring the role of cervical cancer stem cells. Frontiers in Oncology. 2024 Jan 24;13:1277772.

19. Jafari A, Farahani M, Abdollahpour-Alitappeh M, Manzari-Tavakoli A, Yazdani M, Rezaei-Tavirani M. Unveiling diagnostic and therapeutic strategies for cervical cancer: biomarker discovery through proteomics approaches and exploring the role of cervical cancer stem cells. Frontiers in Oncology. 2024 Jan 24;13:1277772.
20. Garg P, Krishna M, Subbalakshmi AR, Ramisetty S, Mohanty A, Kulkarni P, Horne D, Salgia R, Singhal SS. Emerging biomarkers and molecular targets for precision medicine in cervical cancer. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2024 May 1:189106.
21. Garg R, Gaur M, Prajapati BG, Agrawal G, Bhattacharya S, Elossaily GM. Polymeric nanoparticles approach and identification and characterization of novel biomarkers for colon cancer. Results in Chemistry. 2023 Dec 1;6:101167.
22. Ni L, Tang C, Wang Y, Wan J, Charles MG, Zhang Z, Li C, Zeng R, Jin Y, Song P, Wei M. Construction of a miRNA-based nomogram model to predict the prognosis of endometrial cancer. Journal of personalized medicine. 2022 Jul 17;12(7):1154.
23. Bae H, Rha SE, Kim H, Kang J, Shin YR. Predictive Value of Magnetic Resonance Imaging in Risk Stratification and Molecular Classification of Endometrial Cancer. Cancers. 2024 Feb 25;16(5):921.
24. Lasu F, Iddola D. Advancements in Imaging Techniques for Early Detection and Monitoring of Cardiovascular Diseases.
25. Maheshwari E, Nougaret S, Stein EB, Rauch GM, Hwang KP, Stafford RJ, Klopp AH, Soliman PT, Maturen KE, Rockall AG, Lee SI. Update on MRI in evaluation and treatment of endometrial cancer. Radiographics. 2022 Nov;42(7):2112-30.